Apalutamide
http://dbpedia.org/resource/Apalutamide an entity of type: Thing
Apalutamid (im Englischen Apalutamide) ist ein orales, nicht-steroidales Antiandrogen (NSAA), welches zur Behandlung von Prostatakarzinomen eingesetzt wird.
rdf:langString
L'apalutamide est une molécule de la classe des antiandrogènes non stéroïdiens, en cours de test dans le traitement du cancer de la prostate.
rdf:langString
Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. It was the first medication to be approved specifically for the treatment of NM-CRPC.
rdf:langString
rdf:langString
Apalutamid
rdf:langString
Apalutamide
rdf:langString
Apalutamide
xsd:integer
47734223
xsd:integer
1119841764
rdf:langString
BB05
rdf:langString
L02
<perCent>
100.0
xsd:integer
21
xsd:integer
956104
xsd:integer
1361232
xsd:integer
3183409
xsd:integer
28424131
rdf:langString
DB11901
<second>
-345600.0
rdf:langString
Feces: 24%
rdf:langString
Urine: 65%
xsd:integer
4
xsd:integer
15
rdf:langString
Apalutamide molecule ball.png
xsd:integer
4
rdf:langString
D11040
rdf:langString
Rx-only
rdf:langString
POM
rdf:langString
Rx-only
rdf:langString
a618018
rdf:langString
Liver
xsd:integer
5
xsd:integer
2
xsd:integer
24872560
xsd:integer
1
rdf:langString
CNCC1=CF
xsd:integer
1
rdf:langString
HJBWBFZLDZWPHF-UHFFFAOYSA-N
rdf:langString
ARN-509; JNJ-56021927; JNJ-927; A52
rdf:langString
Chemical structures of apalutamide and its predecessors
rdf:langString
left
rdf:langString
Erleada, others
xsd:integer
4
xsd:integer
250
rdf:langString
Apalutamid (im Englischen Apalutamide) ist ein orales, nicht-steroidales Antiandrogen (NSAA), welches zur Behandlung von Prostatakarzinomen eingesetzt wird.
rdf:langString
Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC). It is taken by mouth. Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash, falls, bone fractures, and an underactive thyroid. Rarely, it can cause seizures. The medication has a high potential for drug interactions. Apalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body. Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. It was the first medication to be approved specifically for the treatment of NM-CRPC.
rdf:langString
L'apalutamide est une molécule de la classe des antiandrogènes non stéroïdiens, en cours de test dans le traitement du cancer de la prostate.
rdf:langString
Erleada
rdf:langString
S4
rdf:langString
Rx-only
rdf:langString
Rx-only
rdf:langString
•
rdf:langString
D
rdf:langString
: 95%
rdf:langString
Apalutamide: 96%
xsd:float
100.0
xsd:nonNegativeInteger
34498
rdf:langString
Erleada, others
xsd:string
1361232-32-7
xsd:string
956104-40-8
xsd:string
3183409
xsd:string
DB11901
xsd:string
4T36H88UA7
xsd:string
D11040
xsd:string
a618018
xsd:string
24872560